UCB SA 2018 IR
The report outlines UCB's transition to its first Integrated Annual Report for 2018, focusing on its Patient Value Strategy in immunology, neurology, and bone disorders. Key achievements include reaching over 3.3 million patients with core medicines, achieving a revenue of ’4.6 billion, and advancing its clinical pipeline with key approvals like Evenity in Japan. UCB also made progress on its 2030 environmental goals, reducing its carbon footprint by 30% compared to 2015 and achieving 92% renewable electricity across its sites.
Company: UCB SA
Sector: Health Care
Country: Belgium
Year: 2018
Type: IR
Pages: 288
UCB SA
Integrated Annual Report
The report outlines UCB's transition to its first Integrated Annual Report for 2018, focusing on its Patient Value Strategy in immunology, neurology, and bone disorders. Key achievements include reaching over 3.3 million patients with core medicines, achieving a revenue of ’4.6 billion, and advancing its clinical pipeline with key approvals like Evenity in Japan. UCB also made progress on its 2030 environmental goals, reducing its carbon footprint by 30% compared to 2015 and achieving 92% renewable electricity across its sites.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2018
Reporting Period
Jan 1, 2018 - Dec 31, 2018
Fiscal Year
2018
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees